OBJECTIVE: To identify which breast lesion descriptors in the ACR BI-RADS® MRI lexicon are most strongly associated with the diagnosis of breast cancer when performing breast MR imaging at 3 T. METHODS: 150 patients underwent breast MR imaging at 3 T. Lesion size, morphology and enhancement kinetics were assessed according to the BI-RADS® classification. Sensitivity, specificity and diagnostic accuracy were assessed. The effects of the BI-RADS® descriptors on sensitivity and specificity were evaluated. Data were analysed using logistic regression. Histopathological diagnoses were used as the standard of reference. RESULTS: The sensitivity, specificity and diagnostic accuracy of breast MRI at 3 T was 99%, 81% and 93%, respectively. In univariate analysis, the final diagnosis of malignancy was positively associated with irregular shape (p < 0.001), irregular margin (p < 0.001), heterogeneous enhancement (p < 0.001), Type 3 enhancement kinetics (p = 0.02), increasing patient age (p = 0.02) and larger lesion size (p < 0.001). In multivariate analysis, significant associations with malignancy remained for mass shape (p = 0.06), mass margin (p < 0.001), internal enhancement pattern (p = 0.03) and Type 3 enhancement kinetics (p = 0.06). CONCLUSION: The ACR BI-RADS® breast lesion descriptors that are mostly strongly associated with breast cancer in breast MR imaging at 3 T are lesion shape, lesion margin, internal enhancement pattern and Type 3 enhancement kinetics. KEY POINTS: • 3 Tesla breast MRI allows an accurate diagnosis of breast cancer • The BI-RADS® descriptors help provide a confident diagnosis • The shape, margin, enhancement pattern and kinetics are the most important features • An irregular shape and margin, heterogeneous enhancement and type-3 kinetics indicate malignancy.
OBJECTIVE: To identify which breast lesion descriptors in the ACR BI-RADS® MRI lexicon are most strongly associated with the diagnosis of breast cancer when performing breast MR imaging at 3 T. METHODS: 150 patients underwent breast MR imaging at 3 T. Lesion size, morphology and enhancement kinetics were assessed according to the BI-RADS® classification. Sensitivity, specificity and diagnostic accuracy were assessed. The effects of the BI-RADS® descriptors on sensitivity and specificity were evaluated. Data were analysed using logistic regression. Histopathological diagnoses were used as the standard of reference. RESULTS: The sensitivity, specificity and diagnostic accuracy of breast MRI at 3 T was 99%, 81% and 93%, respectively. In univariate analysis, the final diagnosis of malignancy was positively associated with irregular shape (p < 0.001), irregular margin (p < 0.001), heterogeneous enhancement (p < 0.001), Type 3 enhancement kinetics (p = 0.02), increasing patient age (p = 0.02) and larger lesion size (p < 0.001). In multivariate analysis, significant associations with malignancy remained for mass shape (p = 0.06), mass margin (p < 0.001), internal enhancement pattern (p = 0.03) and Type 3 enhancement kinetics (p = 0.06). CONCLUSION: The ACR BI-RADS® breast lesion descriptors that are mostly strongly associated with breast cancer in breast MR imaging at 3 T are lesion shape, lesion margin, internal enhancement pattern and Type 3 enhancement kinetics. KEY POINTS: • 3 Tesla breast MRI allows an accurate diagnosis of breast cancer • The BI-RADS® descriptors help provide a confident diagnosis • The shape, margin, enhancement pattern and kinetics are the most important features • An irregular shape and margin, heterogeneous enhancement and type-3 kinetics indicate malignancy.
Authors: Carla Boetes; Jeroen Veltman; Lya van Die; Peter Bult; Theo Wobbes; Jelle O Barentsz Journal: Breast Cancer Res Treat Date: 2004-07 Impact factor: 4.872
Authors: Pascal A T Baltzer; Matthias Benndorf; Matthias Dietzel; Mieczyslaw Gajda; Ingo B Runnebaum; Werner A Kaiser Journal: AJR Am J Roentgenol Date: 2010-06 Impact factor: 3.959
Authors: Wendy B Demartini; Brenda F Kurland; Robert L Gutierrez; C Craig Blackmore; Sue Peacock; Constance D Lehman Journal: Eur Radiol Date: 2011-02-27 Impact factor: 5.315
Authors: K Pinker; W Bogner; P Baltzer; S Trattnig; S Gruber; O Abeyakoon; M Bernathova; O Zaric; P Dubsky; Z Bago-Horvath; M Weber; D Leithner; T H Helbich Journal: Eur Radiol Date: 2013-12-05 Impact factor: 5.315
Authors: K Pinker; H Bickel; T H Helbich; S Gruber; P Dubsky; U Pluschnig; M Rudas; Z Bago-Horvath; M Weber; S Trattnig; W Bogner Journal: Eur Radiol Date: 2013-03-16 Impact factor: 5.315
Authors: D Leithner; G J Wengert; T H Helbich; S Thakur; R E Ochoa-Albiztegui; E A Morris; K Pinker Journal: Clin Radiol Date: 2017-12-09 Impact factor: 2.350